Indirect Comparison Between Eltrombopag & Romiplostim

Completed

• Conditions: Thrombocytopaenia
• Interventions: Drug: Romiplostim; Drug: Eltrombopag; Drug: Placebo

• Registration Number: NCT01236014
• Lead Sponsor: GlaxoSmithKline

Brief Summary

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

Detailed Description

An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Study Timeline

• Study Start: 2009-08
• Primary Completion: 2009-10
• Study Completion: 2009-10
• Study First Submitted: 2010-11-04
• Study First Submitted QC: 2010-11-04
• Study First Posted: 2010-11-07
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-06
• Last Update Posted: 2017-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Adults with ITP
• Pre-specified treatment
• Prospective clinical studies with at least 10 patients

Exclusion Criteria

• Adults with ITP for other reasons

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Romiplostim & standard of care	Romiplostim	-
Eltrombopag & standard of care	Eltrombopag	-
Standard of care	Placebo	-

Primary Outcome Measures

Name	Time	Method
Durable response: platelet count of >=50 and <400 Gi/L	6 months
Overall response: either a durable response or a transient platelet response	6 months